首页> 外文期刊>Surgery >Long-term results of endoscopic Histoacryl injection sclerotherapy for gastric variceal bleeding: a 10-year experience.
【24h】

Long-term results of endoscopic Histoacryl injection sclerotherapy for gastric variceal bleeding: a 10-year experience.

机译:内镜下组织丙烯酸注射硬化疗法治疗胃静脉曲张破裂出血的长期结果:10年经验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The long-term efficacy and safety of endoscopic injection of N-butyl-2-cyanoacrylate (Histoacryl) were evaluated as the initial treatment for bleeding gastric varices. PATIENTS AND METHODS: Fifty-two patients with bleeding gastric varices underwent endoscopic injections of Histoacryl for hemostasis over a 10-year period. Histoacryl was injected intravariceally. Among these 52 patients, 32 had active bleeding and 20 had recent bleeding. Most of the varices were large (F2 or F3, 48 cases). After Histoacryl injection, the patients were followed endoscopically with retreatment administered as necessary. The patients were followed for a mean 28.1 months. RESULTS: The rate of initial hemostasis (no bleeding occurred for 48 hours after sclerotherapy) was 96.2%. Cumulative nonbleeding rates were 64.7%, 52.7%, and 48.2% at 1, 5, and 10 years, respectively. When rebleeding occurred, 80.0% was within 1 year after initial injection. Recurrent bleeding was easily stopped with the reinjection of Histoacryl in most patients. The treatment failure-related mortality rate was 4.0% (2 of 52). The cumulative survival rates were 66.9%, 60.4%, and 55.5% at 1, 5, and 10 years, respectively. The mortality depended on either malignancy or liver function (Child-Pugh classification). CONCLUSIONS: These results suggest that Histoacryl injection sclerotherapy is highly effective for the treatment of bleeding gastric varices, with rare complications occurring both acutely and long-term. Therefore, Histoacryl injection sclerotherapy is considered to be the first choice of treatment for bleeding gastric varices, but the rate of recurrent bleeding is so high that further methods or devices still need to be developed in order to prevent gastric variceal rebleeding.
机译:背景:内镜下注射N-丁基-2-氰基丙烯酸酯(Histoacryl)的长期疗效和安全性被评估为胃底静脉曲张破裂出血的初始治疗方法。患者与方法:52例胃底静脉曲张破裂出血的患者在10年的时间内接受了内镜下注射组蛋白丙烯酸止血。将组织丙烯酸经静脉内注射。在这52例患者中,有32例发生活动性出血,而20例有近期出血。大多数静脉曲张较大(F2或F3,48例)。注射组织丙烯酸后,对患者进行内窥镜检查,必要时进行复治。平均随访28.1个月。结果:最初的止血率(硬化疗法后48小时未发生出血)为96.2%。在1年,5年和10年时,累计不出血率分别为64.7%,52.7%和48.2%。当发生再出血时,初次注射后1年内占80.0%。在大多数患者中,通过注射组蛋白丙烯酸很容易阻止复发性出血。与治疗失败相关的死亡率为4.0%(52之2)。在1年,5年和10年时的累积生存率分别为66.9%,60.4%和55.5%。死亡率取决于恶性肿瘤或肝功能(Child-Pugh分类)。结论:这些结果表明,Histoacryl注射硬化剂治疗出血性胃底静脉曲张非常有效,急性和长期并发症很少见。因此,Histoacryl注射硬化疗法被认为是治疗胃底静脉曲张破裂出血的首选方法,但是复发性出血的发生率如此之高,以至于需要进一步开发方法或装置以防止胃静脉曲张再出血。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号